Furthermore, because of the significant correlation of H19, and SPRY4‐IT1 lncRNAs with clinicopathological traits and their excellent power in discriminating breast cancer from healthy individuals, they could be considered as the prognostic biomarkers and novel therapeutic targets in breast cancer. Here, SPRY4 is linked to breast carcinoma.